Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 12/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.37 |
| ▸ | KIT | P10721 | 3/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15969274 | 0.86 | CSF1R (0.37) | CSF1RKITNTRK1LCKAXL | |
| SCHEMBL4997574 | 0.79 | CSF1R (0.38) | CSF1RHDAC1HDAC2KITNTRK1 | |
| SCHEMBL1857988 | 0.76 | CSF1R (0.51) | CSF1RHDAC1HDAC2KITHDAC3 | |
| SCHEMBL1860797 | 0.76 | CSF1R (0.51) | CSF1RHDAC1HDAC2KITHDAC3 | |
| SCHEMBL16605567 | 0.73 | HDAC1 (0.52) | CSF1RHDAC1HDAC2KITHDAC3 | |
| SCHEMBL25209067 | 0.72 | CSF1R (0.37) | CSF1RHDAC1HDAC2KITHDAC3 | |
| SCHEMBL1860036 | 0.72 | CSF1R (0.52) | CSF1RHDAC1HDAC2KITHDAC3 | |
| SCHEMBL2914743 | 0.72 | CSF1R (0.49) | CSF1RHDAC1HDAC2KIT | |
| SCHEMBL3088143 | 0.72 | KIT (0.60) | CSF1RHDAC1HDAC2KITNTRK1 | |
| SCHEMBL25208304 | 0.72 | CSF1R (0.36) | CSF1RHDAC1HDAC2KITHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885HDAC1 1847/4885HDAC2 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.